See www.noxopharm.com
Noxopharm is an Australian drug development company with offices in Sydney, Melbourne and Hong Kong. The Company is aiming to become a global leader in the field of radio-sensitisation and chemo-sensitisation with a number of first-in-class drugs capable of making existing anti-cancer therapies work more effectively and safer.
Noxopharm listed on the Australian Securities Exchange (ASX:NOX) on August 9, 2016. Since then:
• We have identified and reported on how our first pipeline drug, NOX66, works in the body. In the process, IP was created that we considered highly valuable and for which patents have been applied. This proprietary drug delivery technology is called LIPROSE drug-shielding and has, we believe, implications for a range of other drugs and other uses.
• We got underway with the first-in-human clinical study of NOX66, with 11 cancer patients currently being treated with NOX66 + chemotherapy drug, carboplatin.
• We reported on how well tolerated NOX66 was in these patients, opening the way for using NOX66 in a range of other clinical studies.
• A number of Australian hospitals have signed up to 3 other clinical studies involving latestage prostate cancer studies involving NOX66 + radiotherapy, with patient enrolment expected within a matter of weeks.
• Planning for the large-scale manufacture of NOX66 to GMP specifications has been undertaken for Phase 3 studies projected to start late-2018.
• The ability of NOX66 to cross the usually impenetrable blood-brain barrier to reach the brain was confirmed in animals, opening the way to use NOX66 to treat both primary and secondary cancers of the brain. A range of pre-clinical studies currently are underway in Australia and Hong Kong with a view to being in the clinic in 2018.
• A strategic review of the clinical development plan for NOX66 was undertaken in association with our medical advisors that identified NOX66 in combination with radiotherapy in latestage prostate and lung cancers as the preferred clinical indications for Phase 3 registration studies.
• A presentation has been accepted for the European Society of Medical Oncology (ESMO) conference in Madrid in Sept 2017. ESMO is the largest cancer conference held in Europe each year. Data to be presented concerns the first-in-human NOX66 + carboplatin study currently underway.
• We made a strategic commitment to the treatment of Rare Cancers. These less common cancers account collectively for up to 40% of cancer deaths but generally do not undergo clinical studies because of their rarity. NOX plans on testing the benefit of NOX66 in these
patients in the hope that any clinical benefit will form part of any subsequent marketing approval.
• We undertook 2 drug programs for non-oncology purposes based on the LIPROSE technology platform. These two programs built on the ability of LIPROSE to deliver certain classes of drugs into the brain to treat neurological diseases.
Add to My Watchlist
What is My Watchlist?
